Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Klump Michael A

2. Issuer Name and Ticker or Trading Symbol
CytoDyn Inc. [CYDY]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	_____ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

(Last)

(First)

(Middle)

1111 MAIN STREET, SUITE 660

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2019

(Street)

VANCOUVER, WA 98660

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/08/2019		M		1,000,000	A	$ 0.4	8,034,520	I	See Footnote ⁽¹⁾
Common Stock	05/08/2019		M		1,933,333	A	$ 0.4	9,967,853	I	See Footnote ⁽¹⁾
Common Stock	05/08/2019		M		500,000	A	$ 0.3	10,467,853	I	See Footnote ⁽¹⁾
Common Stock	05/08/2019		M		66,667	A	$ 0.4	66,667	I	By the Klump Children's Gift Trust
Common Stock	05/08/2019		M		125,000	A	$ 0.4	125,000	D
Common Stock	05/08/2019		A		1,716,666	A	⁽²⁾	12,184,519	I	See Footnote ⁽¹⁾
Common Stock	05/08/2019		A		33,333	A	⁽²⁾	100,000	I	By the Klump Children's Gift Trust
Common Stock	05/08/2019		A		62,500	A	⁽²⁾	187,500	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Warrant (Right to Buy)

$ 0.75

05/08/2019

1,000,000

02/16/2018

02/16/2023

Common Stock

1,000,000

⁽²⁾

See Footnote ⁽¹⁾

Warrant (Right to Buy)

$ 0.4

05/08/2019

1,000,000

02/16/2018

02/16/2023

Common Stock

1,000,000

⁽²⁾

1,000,000

See Footnote ⁽¹⁾

Warrant (Right to Buy)

$ 0.4

05/08/2019

1,000,000

02/16/2018

02/16/2023

Common Stock

1,000,000

$ 0

See Footnote ⁽¹⁾

Warrant (Right to Buy)

$ 1

05/08/2019

1,933,333

12/12/2016

12/12/2021

Common Stock

1,933,333

⁽²⁾

See Footnote ⁽¹⁾

Warrant (Right to Buy)

$ 0.4

05/08/2019

1,933,333

12/12/2016

12/12/2021

Common Stock

1,933,333

⁽²⁾

1,933,333

See Footnote ⁽¹⁾

Warrant (Right to Buy)

$ 0.4

05/08/2019

1,933,333

12/12/2016

12/12/2021

Common Stock

1,933,333

$ 0

See Footnote ⁽¹⁾

Warrant (Right to Buy)

$ 0.3

05/08/2019

500,000

01/08/2019

01/08/2024

Common Stock

500,000

$ 0

See Footnote ⁽¹⁾

Warrant (Right to Buy)

$ 1

05/08/2019

66,667

12/12/2016

12/12/2021

Common Stock

66,667

⁽²⁾

By the Klump Children's Gift Trust

Warrant (Right to Buy)

$ 0.4

05/08/2019

66,667

12/12/2016

12/12/2021

Common Stock

66,667

⁽²⁾

66,667

By the Klump Children's Gift Trust

Warrant (Right to Buy)

$ 0.4

05/08/2019

66,667

12/12/2016

12/12/2021

Common Stock

66,667

$ 0

By the Klump Children's Gift Trust

Warrant (Right to Buy)

$ 1.35

05/08/2019

125,000

04/26/2016

04/26/2021

Common Stock

125,000

⁽²⁾

Warrant (Right to Buy)

$ 0.4

05/08/2019

125,000

04/26/2016

04/26/2021

Common Stock

125,000

⁽²⁾

125,000

Warrant (Right to Buy)

$ 0.4

05/08/2019

125,000

04/26/2016

04/26/2021

Common Stock

125,000

$ 0

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Klump Michael A 1111 MAIN STREET, SUITE 660 VANCOUVER, WA 98660	X

Signatures

/s/ Michael D. Mulholland, as attorney-in-fact		05/10/2019
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The reported securities of CytoDyn Inc. (the "Company") are held by Argonne Trading, LLC, a Georgia limited liability company ("Argonne Trading"). Argonne Capital Group, LLC, a Georgia limited liability company ("Argonne Capital"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein.
(2)	On May 8, 2019, the Company entered into Warrant Exercise Agreements with Mr. Klump, Argonne Capital and the Klump Children's Gift Trust, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the "Warrants") to purchase shares of the Company's common stock, par value $0.001 per share ("Common Stock") beneficially owned by Mr. Klump, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.